CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that has become one of the most widely studied peptides for stimulating endogenous growth hormone production. Available in two variants — with and without Drug Affinity Complex (DAC) — it offers researchers flexible options for studying GH kinetics.

In this comprehensive 2026 guide, we break down everything researchers need to know about CJC-1295 — from its mechanism of action and dosing protocols used in published studies, to practical considerations like sourcing, storage, and stacking. Whether you're evaluating CJC-1295 for the first time or looking to deepen your understanding, this article provides a research-backed foundation.

Unlike GHRPs (Growth Hormone Releasing Peptides) such as Ipamorelin that mimic ghrelin, CJC-1295 works on the GHRH pathway, stimulating the pituitary to produce GH through a complementary mechanism. This distinction is key to understanding why CJC-1295 and Ipamorelin are so frequently studied together — they activate GH release through two independent pathways for synergistic amplification.

How CJC-1295 Works: Mechanism of Action

CJC-1295 binds to the GHRH receptor on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and release of growth hormone. It is a modified version of GHRH (1-29) with amino acid substitutions that make it resistant to enzymatic degradation, extending its biological activity.

The DAC (Drug Affinity Complex) variant includes a lysine linker that allows CJC-1295 to bind covalently to serum albumin after injection. This dramatically extends its half-life from approximately 30 minutes (no DAC) to 6-8 days (with DAC), providing sustained GH elevation over days rather than hours.

The no-DAC variant (sometimes called Modified GRF 1-29 or Mod GRF) produces acute GH pulses similar to the body's natural release pattern. This pulsatile approach is generally preferred in research because it better maintains pituitary sensitivity and more closely mimics physiological GH secretion.

Key Research Findings & Potential Benefits

Preclinical and clinical studies have examined CJC-1295 across several outcome measures. Below are the most frequently cited findings in the research literature:

• Sustained GH Elevation: Both variants significantly increase GH levels, with the DAC variant providing sustained elevation for days and the no-DAC variant producing acute pulses lasting 2-3 hours.
• Increased IGF-1 Levels: Elevated GH leads to increased hepatic production of IGF-1, a key mediator of GH's anabolic, metabolic, and regenerative effects throughout the body.
• Improved Body Composition: Studies show favorable changes in lean mass-to-fat ratio, with both increased muscle protein synthesis and enhanced lipolysis (fat breakdown).
• Enhanced Recovery: Elevated GH and IGF-1 promote collagen synthesis, tissue repair, and faster recovery from physical stress or injury.
• Improved Sleep Quality: Growth hormone is released in its largest pulses during slow-wave (deep) sleep. CJC-1295 administered in the evening may support deeper sleep architecture.
• Skin and Connective Tissue: GH stimulates collagen production, which can improve skin elasticity, reduce wrinkle depth, and strengthen tendons and ligaments over time.

CJC-1295 provides a reliable, well-studied method for elevating endogenous GH levels. Its effects are mediated primarily through IGF-1 elevation and the downstream anabolic, metabolic, and regenerative processes that GH governs.

Dosing Protocols in Research Literature

Important: The dosing information below is compiled from published research studies and is presented for educational reference only. This is not medical advice.

For the no-DAC variant, timing follows the same principles as Ipamorelin — administer on an empty stomach, ideally before bed or upon waking. The DAC variant, with its extended half-life, can be injected once or twice weekly. When combining with Ipamorelin, both peptides can be reconstituted separately and drawn into the same syringe for convenience.

Reported Side Effects & Safety Considerations

No compound is without potential adverse effects. Researchers and participants in clinical trials have reported the following:

• Flushing / Warmth: A brief sensation of warmth or facial flushing after injection is common and typically resolves within 15-30 minutes.
• Water Retention: Mild water retention, particularly in the hands and feet, can occur with elevated GH levels. This is dose-dependent and usually manageable.
• Tingling / Numbness: Paresthesia (tingling in extremities) is a known side effect of elevated GH, similar to what is seen with exogenous HGH administration.
• Increased Hunger: More pronounced with the DAC variant due to sustained GH elevation. The no-DAC variant has a more modest effect on appetite.

CJC-1295 has been studied in multiple Phase I and II clinical trials with a generally favorable safety profile. The no-DAC variant is considered safer for long-term protocols due to its pulsatile GH release pattern, which better maintains hypothalamic-pituitary feedback mechanisms.

Popular Stacking Combinations

In research settings, CJC-1295 is sometimes studied alongside other compounds. Common combinations include:

• Ipamorelin: The gold standard GH peptide stack. CJC-1295 (GHRH pathway) and Ipamorelin (ghrelin pathway) activate GH release through two independent mechanisms, producing greater GH output than either alone.
• BPC-157 + TB-500: For recovery-focused protocols, adding healing peptides to the GH-elevating foundation of CJC-1295 creates a comprehensive regenerative environment.
• Tesamorelin: Another GHRH analog (FDA-approved for HIV-related lipodystrophy), sometimes alternated with CJC-1295 in research protocols studying visceral fat reduction.

Stacking compounds increases complexity and potential interactions. Researchers should approach combinations methodically, introducing one variable at a time when possible.

CJC-1295 vs Alternatives: How It Compares

Understanding how CJC-1295 compares to similar compounds helps researchers select the right tool for their specific protocol. Here is a side-by-side comparison:

CJC-1295 with DAC offers the longest-acting GHRH analog available, reducing dosing frequency significantly. For researchers who prefer natural pulsatile patterns, Mod GRF (1-29) paired with a GHRP may be preferable.

Where to Source Research-Grade CJC-1295

Quality and purity are paramount when sourcing research chemicals. Key factors to consider include:

• Third-party testing: Look for vendors that publish Certificates of Analysis (CoA) with HPLC or mass spectrometry verification showing purity of 98% or higher.
• Reputation and transparency: Established vendors with a track record of consistent quality, clear labeling, and responsive customer support are preferred.
• Pricing comparisons: Use comparison platforms like DiscountChems to evaluate price-per-milligram across multiple vendors and find the best value without compromising quality.
• DAC vs no-DAC labeling: Ensure the vendor clearly specifies which variant you are purchasing. Some listings simply say 'CJC-1295' without specifying DAC status, leading to confusion. The no-DAC variant may also be labeled as 'Mod GRF 1-29.'
• Combination products: Some vendors sell pre-mixed CJC-1295/Ipamorelin blends. While convenient, verify the peptide ratios and purity testing for blended products.

Always verify current stock, batch numbers, and testing documentation before placing an order for research purposes.

Frequently Asked Questions

What is the difference between CJC-1295 with DAC and without DAC?

The Drug Affinity Complex (DAC) is a molecular attachment that allows CJC-1295 to bind to albumin in the bloodstream, extending its half-life from ~30 minutes to 6-8 days. The DAC variant provides sustained GH elevation (like a slow drip), while the no-DAC variant produces acute GH pulses that mimic the body's natural release pattern. Most researchers prefer no-DAC for long-term use due to better pituitary sensitivity preservation.

Can CJC-1295 replace HGH?

CJC-1295 stimulates your body's own GH production rather than introducing exogenous hormone. The peak GH levels achieved are generally lower than pharmaceutical HGH doses, but the approach is considered more physiologically compatible. CJC-1295 maintains natural feedback loops, while exogenous HGH can suppress endogenous production.

How long until CJC-1295 effects are noticeable?

GH elevation occurs within minutes of injection (no-DAC) or hours (with DAC). However, the downstream effects — improved sleep, recovery, body composition changes — typically become noticeable after 4-8 weeks of consistent use. IGF-1 levels peak at approximately 8-12 weeks.

Is CJC-1295 the same as Sermorelin?

Both are GHRH analogs, but they differ in structure and potency. Sermorelin is GHRH (1-29) without modifications, giving it a shorter half-life. CJC-1295 has amino acid substitutions that resist enzymatic breakdown, making it more potent per dose. The DAC variant further extends its activity. CJC-1295 is generally considered the more effective research tool.

References & Research Citations

The information in this article draws from the following published research:

1. [1] Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(3):799-805.
2. [2] Ionescu M, Bharat V. Pulsatile GH secretion after intravenous or subcutaneous CJC-1295 administration in healthy volunteers. J Clin Endocrinol Metab. 2006;91(1):48-52.
3. [3] Alba M, et al. Once-daily CJC-1295 increases GH and IGF-1 levels in GH deficient adults. Growth Horm IGF Res. 2006;16(5):301-310.

Note: This list is not exhaustive. Additional studies may exist. Always consult primary sources for the most current research data.

Related Resources on DiscountChems

• CJC-1295 price comparison
• Growth hormone peptides guide
• All peptides
• What are peptides guide
• Peptide storage guide
• Research stacks
• Peptide calculator
• Vendor reviews

Conclusion

CJC-1295 remains a cornerstone of growth hormone peptide research, offering a well-characterized, reliable method for elevating endogenous GH production. Whether used alone or in the widely-studied combination with Ipamorelin, it provides researchers with a versatile tool for studying the broad downstream effects of growth hormone elevation — from body composition and recovery to sleep quality and tissue regeneration.

For the latest pricing data and vendor comparisons for CJC-1295, visit the DiscountChems CJC-1295 comparison page. Prices are updated regularly so you can make informed sourcing decisions.

Have questions or want to discuss research protocols? Join the DadBod2Fit community on Skool to connect with other researchers and stay up to date on the latest developments.